Michelle Therese Simmers, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 51 N Main St, Boonton, NJ 07005 Phone: 973-263-3000 |
Stephanie Sclafani Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 51 N Main St, Boonton, NJ 07005 Phone: 973-794-3390 Fax: 973-794-3391 |
Michael Roufaeal Occupational Therapist Medicare: Medicare Enrolled Practice Location: 219 Toner Rd, Boonton, NJ 07005 Phone: 973-735-7848 |
Mrs. Jennifer Lynn Wagner, MSOTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 206 Deerlea Ln, Boonton, NJ 07005 Phone: 973-632-6487 |
Mrs. Linda Jean Hogoboom, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 21 Chestnut St, Boonton, NJ 07005 Phone: 845-893-6214 |
News Archive
At the 59th annual meeting of the American Society of Human Genetics, Illumina, Inc. today announced its 2010 roadmap for the Infinium whole-genome genotyping platform, offering products capable of analyzing up to five million (5M) variants per sample.
Nature News reports on last week's announcement of preliminary results from a large clinical trial testing the efficacy of GlaxoSmithKline's (GSK) RTS,S malaria vaccine, writing that while media coverage of the announcement touted it as a "big breakthrough in the long campaign to create a malaria vaccine," "several leading vaccine researchers, who are critical of the unusual decision to publish partial trial data, argue that the results raise questions about whether the RTS,S/AS01 candidate vaccine can actually win approval."
Researchers with the Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have secured $4 million in funding from the National Institutes of Health (NIH)/National Cancer Institute to establish an HIV-associated Malignancy Research Center (HAMRC) focused on lung cancer in East Africa.
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds - IMGN901 and SAR3419 - are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.
New research from Columbia University Medical Center is challenging the traditional explanation for the causes of the most common type of heart failure, traditionally called diastolic heart failure.
› Verified 9 days ago